Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + paclitaxel polymer micelles + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy is a chemo-immunotherapy regimen being evaluated for the treatment of stage III unresectable non-small cell lung cancer (NSCLC). It consists of two monoclonal antibodies developed by Akeso Biopharma: **iparomlimab** (AK105), a humanized IgG1 antibody targeting the programmed cell death protein 1 (PD-1) receptor, and **tuvonralimab** (AK107), a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The combination of these two antibodies is also referred to as **AK130**. These immunotherapies are administered alongside **paclitaxel polymer micelles**, a nanoparticle formulation designed to improve the solubility and delivery of paclitaxel, and a platinum-based chemotherapy agent, either **cisplatin** or **carboplatin**. The regimen aims to enhance anti-tumor immune responses through dual checkpoint blockade while leveraging the cytotoxic effects of microtubule stabilization and DNA cross-linking provided by the chemotherapy components.
- Brand names
- Penpulimab
- Other names
- ApalotamabAK-105AK105AK 105AK-107AK107AK 107AK-130AK130AK 130Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + paclitaxel polymer micelles + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + paclitaxel polymer micelles + cisplatin + carboplatin.